VVD-065 / Bayer - LARVOL DELTA

Therapeutic targeting of NRF2 increases sensitivity to chemotherapy in various solid tumors (EORTC-NCI-AACR 2024) - "Consistent with NRF2's known role in chemoresistance, combining VVD-065 with chemotherapy agents such as cisplatin, nab-paclitaxel, 5-FU, and gemcitabine led to marked improvements compared to monotherapy groups...Our preclinical PDX trial revealed that squamous cancer types are particularly susceptible to NRF2 depletion. Additionally, combining VVD-065 with SOC chemotherapy resulted in more profound and durable responses."

Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Uterine Cancer • BRAF • KRAS